A Danish pharmaceutical company is firing back at a rival's claims that its own products are more effective in treating obesity than the popular medication Wegovy. The rival company had previously cited outdated data to support its claims, according to the Danish group. The Danish company is now accusing its competitor of misrepresenting the facts, and is pushing back against what it sees as a misleading marketing campaign. As the battle for market share in the lucrative obesity medication market heats up, the Danish company's response is likely to have significant implications for patients and healthcare providers alike.
Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy
